Ampio Pharmaceuticals Receives Approval to Expand Enrollment of its AP-019 Phase II Study to India

Go back to Ampio Pharmaceuticals Receives Approval to Expand Enrollment of its AP-019 Phase II Study to India
AMPIO PHARMACEUTICALS, Inc. (NYSE: AMPE) Delayed: 1.74 --0 (-0%)
Previous Close $1.74    52 Week High $4.32 
Open $1.76    52 Week Low $0.59 
Day High $1.77    P/E N/A 
Day Low $1.73    EPS $-0.63 
Volume 200,226